Suppliers and packagers for generic pharmaceutical drug: MISOPROSTOL

MISOPROSTOL

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pfizer	CYTOTEC	misoprostol	TABLET;ORAL	019268	NDA	Pfizer Laboratories Div Pfizer Inc	0025-1451-34	100 BLISTER PACK in 1 CARTON (0025-1451-34) / 1 TABLET in 1 BLISTER PACK	1986-12-27
Pfizer	CYTOTEC	misoprostol	TABLET;ORAL	019268	NDA	Pfizer Laboratories Div Pfizer Inc	0025-1451-60	60 TABLET in 1 BOTTLE, UNIT-DOSE (0025-1451-60)	1986-12-27
Pfizer	CYTOTEC	misoprostol	TABLET;ORAL	019268	NDA	Pfizer Laboratories Div Pfizer Inc	0025-1461-31	100 TABLET in 1 BOTTLE, UNIT-DOSE (0025-1461-31)	1986-12-27
Pfizer	CYTOTEC	misoprostol	TABLET;ORAL	019268	NDA	Pfizer Laboratories Div Pfizer Inc	0025-1461-60	60 TABLET in 1 BOTTLE, UNIT-DOSE (0025-1461-60)	1986-12-27

Misoprostol Suppliers Analysis

Last updated: February 19, 2026

This report details key global suppliers of misoprostol, a synthetic prostaglandin E1 analog. The analysis focuses on manufacturing capabilities, regulatory approvals, and market presence relevant to pharmaceutical development and supply chain management.

Who are the Major Global Manufacturers of Misoprostol?

Several companies are significant producers of misoprostol active pharmaceutical ingredient (API) and finished dosage forms. These entities operate under varying regulatory frameworks and possess distinct production capacities.

• Pfizer Inc. is a primary manufacturer of misoprostol, marketed under the brand name Cytotec. The company holds numerous patents related to misoprostol and its manufacturing processes. Pfizer's global manufacturing network is extensive, ensuring broad market reach. The company's primary focus has been on its branded product, though it also supplies API to other entities.
• Sun Pharmaceutical Industries Ltd. is a major Indian pharmaceutical company that produces misoprostol API and finished products. Sun Pharma has a significant generics portfolio and operates manufacturing facilities compliant with international regulatory standards, including US FDA and EMA.
• Teva Pharmaceutical Industries Ltd., a global leader in generics, also manufactures misoprostol. Teva's production is supported by its robust API manufacturing capabilities and extensive distribution network across multiple continents.
• Mylan N.V. (now part of Viatris) has been a producer of misoprostol, focusing on generic versions. The company's manufacturing sites are subject to rigorous quality control and regulatory oversight.
• Bristol-Myers Squibb Company historically had a role in misoprostol production and related research, though current primary API manufacturing is concentrated with other specialized producers.
• Various Chinese API Manufacturers: A significant portion of global misoprostol API production originates from China. Companies like Zhejiang Hailysheng Pharmaceutical Co., Ltd. and Hubei Guangji Pharmaceutical Co., Ltd. are identified as key suppliers. These manufacturers often supply API in bulk to formulation companies worldwide. Their operations are subject to China's NMPA (National Medical Products Administration) regulations, and many seek to comply with international GMP standards to serve export markets.

Table 1 outlines selected key suppliers and their known market presence for misoprostol.

Company Name	Primary Role	Geographic Focus (Manufacturing)	Key Regulatory Compliance (Examples)
Pfizer Inc.	Branded/API Supplier	Global	US FDA, EMA, PMDA (Japan)
Sun Pharmaceutical Industries Ltd.	API/Generics	India, Global	US FDA, EMA, TGA (Australia)
Teva Pharmaceutical Industries Ltd.	API/Generics	Global	US FDA, EMA, Health Canada
Viatris Inc. (formerly Mylan N.V.)	API/Generics	Global	US FDA, EMA, MHRA (UK)
Zhejiang Hailysheng Pharmaceutical Co., Ltd.	API Manufacturer	China	NMPA, GMP (seeking international)
Hubei Guangji Pharmaceutical Co., Ltd.	API Manufacturer	China	NMPA, GMP (seeking international)

What is the Regulatory Landscape for Misoprostol Production?

Misoprostol is a prescription drug and its manufacture is subject to stringent regulatory oversight by health authorities worldwide. Compliance with Good Manufacturing Practices (GMP) is mandatory for all API and finished product manufacturers.

• US Food and Drug Administration (FDA): Manufacturers supplying to the U.S. market must adhere to FDA regulations, including those outlined in 21 CFR Parts 210 and 211. API manufacturers must register their facilities with the FDA and undergo inspections. Drug Master Files (DMFs) are commonly submitted for API.
• European Medicines Agency (EMA): Companies operating within the European Union must comply with EMA guidelines and have manufacturing sites inspected and certified by national competent authorities. GMP certificates are required.
• Other National Regulatory Bodies: Agencies like Japan's Pharmaceuticals and Medical Devices Agency (PMDA), Canada's Health Canada, and Australia's Therapeutic Goods Administration (TGA) have their own specific requirements for drug manufacturing and approval.
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH): Adherence to ICH guidelines (e.g., ICH Q7 for API GMP) is increasingly important for global market access.

The status of a manufacturer's facility with these agencies is a critical indicator of their ability to supply compliant misoprostol. Recent FDA warning letters or import alerts related to a manufacturer can significantly disrupt supply chains.

What are the Key Patents and Intellectual Property Considerations?

The patent landscape for misoprostol itself is largely expired, as the drug was first approved decades ago. However, patents may still exist for:

• Specific Polymorphs: Novel crystalline forms of misoprostol with improved stability or bioavailability.
• Manufacturing Processes: New, more efficient, or environmentally friendly synthetic routes.
• Formulations: Novel delivery systems, combination therapies, or extended-release formulations.
• Methods of Use: New therapeutic indications for misoprostol, although these are typically patented by the innovator company and can create market exclusivity for that specific use.

Companies seeking to enter the market with generic misoprostol must conduct thorough freedom-to-operate (FTO) analyses to ensure they do not infringe on any existing, valid patents. Patent expiration dates for key composition-of-matter patents on misoprostol generally fall into the past, but process and formulation patents can still pose barriers. For instance, patents related to specific manufacturing yields or impurity profiles can influence manufacturing choices.

How Does Supply Chain Robustness Vary Among Suppliers?

Supply chain robustness for misoprostol is influenced by several factors:

• Geographic Concentration of Manufacturing: Over-reliance on a single region for API production can create vulnerability to geopolitical events, natural disasters, or regulatory crackdowns. The significant presence of Chinese API manufacturers highlights this potential risk.
• Dual Sourcing Strategy: Pharmaceutical companies often seek to qualify multiple API suppliers to mitigate risk. This requires significant investment in auditing and qualification of each supplier.
• Vertical Integration: Companies that control both API manufacturing and finished dosage form production may offer greater supply chain stability.
• Regulatory Compliance History: A consistent record of successful inspections and no regulatory enforcement actions (e.g., warning letters) indicates a more reliable supplier.
• Financial Stability of the Supplier: The long-term viability of a supplier is crucial for ensuring consistent supply.

For example, a supplier solely reliant on a single manufacturing site in a region prone to earthquakes or political instability presents a higher risk than a multi-site, globally diversified manufacturer with a strong regulatory track record.

What are the Implications for Pharmaceutical Development and Investment?

The misoprostol supply landscape has direct implications for pharmaceutical companies involved in:

• Generic Drug Development: Securing reliable, cost-effective API sources is paramount. Companies must identify suppliers with proven GMP compliance and competitive pricing. The expiration of key patents allows for generic competition, driving demand for API from multiple sources.
• New Formulation Development: Innovators developing novel misoprostol formulations need to partner with API suppliers capable of meeting specific purity profiles and particle size requirements, which may differ from standard API specifications.
• Investment Decisions: Investors evaluating companies with misoprostol-related products need to assess the security and cost-effectiveness of their supply chain. Dependence on single-source, non-compliant, or financially unstable suppliers can pose significant investment risks. Diversification of API sourcing and robust quality agreements are key indicators of supply chain resilience.

The market for misoprostol is characterized by established global players and a significant number of API producers, particularly in Asia. Strategic sourcing and rigorous due diligence are essential for any entity relying on this API.

Key Takeaways

• Major global suppliers of misoprostol API include Pfizer (branded and API), Sun Pharma, Teva, Viatris, and numerous Chinese manufacturers like Zhejiang Hailysheng and Hubei Guangji.
• All manufacturers must comply with stringent GMP regulations from authorities like the FDA and EMA.
• While composition-of-matter patents for misoprostol have expired, patents on specific processes, polymorphs, and formulations can still exist.
• Supply chain robustness is influenced by manufacturing location diversity, regulatory compliance history, and dual sourcing strategies.
• Pharmaceutical development and investment decisions are significantly impacted by the availability, quality, and cost of misoprostol API.

FAQs

1. What is the typical lead time for sourcing misoprostol API from major international suppliers?

Lead times can vary significantly based on order volume, existing inventory, production schedules, and shipping logistics. However, for substantial orders, lead times from qualification to delivery typically range from 3 to 9 months, assuming a qualified supplier with active production capacity. This includes time for quality agreements, initial sample testing, and production batch scheduling.

2. How is the purity of misoprostol API typically assessed by regulatory bodies?

Purity is assessed through rigorous analytical testing, including High-Performance Liquid Chromatography (HPLC) to quantify misoprostol and identify related substances (impurities), Gas Chromatography (GC) for residual solvents, and spectroscopic methods (e.g., IR, NMR) for structural confirmation. Regulatory bodies require API to meet pharmacopeial standards (e.g., USP, EP) which set specific limits for known and unknown impurities, heavy metals, and water content.

3. Can a single misoprostol API supplier meet the needs of multiple generic drug manufacturers simultaneously?

Yes, larger API manufacturers often have the capacity to supply multiple generic drug companies. However, supply agreements will typically stipulate allocation limits, and the overall availability can become constrained if demand from many generics producers coincides with production issues or increased demand for the finished product. Companies often mitigate this risk by qualifying at least two API suppliers.

4. What are the common challenges faced by new entrants aiming to become misoprostol API suppliers?

New entrants face significant challenges including:

• High Capital Investment: Establishing GMP-compliant manufacturing facilities is costly.
• Regulatory Hurdles: Obtaining approval from major regulatory bodies like the FDA and EMA requires extensive documentation, validation, and successful site inspections, which can take years and considerable resources.
• Competition: The market is competitive, with established players already holding market share and established relationships with formulators.
• Demonstrating Reliability: Building a track record of consistent quality and supply is crucial for gaining trust.

5. How does the cost of misoprostol API fluctuate, and what drives these changes?

API costs are influenced by raw material prices, energy costs, labor expenses, economies of scale in production, and the stringency of regulatory compliance. Fluctuations can occur due to:

• Supply-Demand Dynamics: Increased demand from new markets or unexpected supply disruptions (e.g., plant shutdowns, raw material shortages) can drive prices up.
• Regulatory Costs: Implementing and maintaining compliance with evolving GMP standards can increase manufacturing overhead, which may be passed on to buyers.
• Competition: Increased competition among API manufacturers, especially from regions with lower production costs, can lead to price pressures.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Code of Federal Regulations Title 21. Retrieved from https://www.ecfr.gov/ [2] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.ema.europa.eu/ [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/ [4] Various Company Annual Reports and Public Filings (e.g., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.). (Accessed 2023-2024). [5] Pharmaceutical supply chain databases and industry reports. (Accessed 2023-2024).